Endocyte to Present at the Wedbush PacGrow Life Sciences Management Access Conference
WEST LAFAYETTE, Ind., Aug. 7, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that Ron Ellis, president and CEO of Endocyte, will present at the Wedbush PacGrow Life Sciences Management Access Conference on Wednesday, Aug. 15, at 2:30 p.m. EDT. The conference is being held at the Le Parker Meridien, New York.
A live audio webcast of the Company's presentation can be accessed at http://wsw.com/webcast/wedbush21/ecyt/ or under "Events & Presentations" in the Investor Relations section of Endocyte's website at www.endocyte.com . The webcast will be archived shortly after the live event and a replay will be available on the Company's website for 90 days following the conference.
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.
For additional information, please visit Endocyte's website at www.endocyte.com .
CONTACT: Stephanie Ascher, Stern Investor Relations, Inc. (212) 362-1200, firstname.lastname@example.org Martina Schwarzkopf, Ph.D., Russo Partners (212) 845-4292 email@example.com Tony Russo, Ph.D., Russo Partners (212) 845-4251 firstname.lastname@example.orgSource: Endocyte, Inc. 2012 GlobeNewswire, Inc.